Australia markets open in 5 hours 42 minutes

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (603896.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
45.81-0.75 (-1.61%)
At close: 03:00PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 9.07B
Enterprise value 8.37B
Trailing P/E 36.78
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)11.31
Price/book (mrq)5.38
Enterprise value/revenue 10.52
Enterprise value/EBITDA 33.03

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 315.40%
S&P500 52-week change 3-7.75%
52-week high 347.16
52-week low 331.82
50-day moving average 340.06
200-day moving average 337.72

Share statistics

Avg vol (3-month) 33.41M
Avg vol (10-day) 32.69M
Shares outstanding 5197.2M
Implied shares outstanding 6N/A
Float 894.02M
% held by insiders 148.01%
% held by institutions 19.77%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.41
Forward annual dividend yield 40.92%
Trailing annual dividend rate 30.31
Trailing annual dividend yield 30.67%
5-year average dividend yield 4N/A
Payout ratio 432.38%
Dividend date 3N/A
Ex-dividend date 426 May 2022
Last split factor 21:1
Last split date 326 May 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Sept 2022

Profitability

Profit margin 30.68%
Operating margin (ttm)27.53%

Management effectiveness

Return on assets (ttm)6.74%
Return on equity (ttm)15.28%

Income statement

Revenue (ttm)795.04M
Revenue per share (ttm)4.06
Quarterly revenue growth (yoy)-2.50%
Gross profit (ttm)640.76M
EBITDA 266.12M
Net income avi to common (ttm)243.91M
Diluted EPS (ttm)1.25
Quarterly earnings growth (yoy)50.10%

Balance sheet

Total cash (mrq)1B
Total cash per share (mrq)5.23
Total debt (mrq)298.56M
Total debt/equity (mrq)17.69
Current ratio (mrq)3.15
Book value per share (mrq)8.78

Cash flow statement

Operating cash flow (ttm)333.98M
Levered free cash flow (ttm)-10.93M